FDA Grants Approval for Tofacitinib Citrate ANDA218900 by Saptalis Pharmaceuticals
The FDA has granted approval for ANDA218900, a generic version of Tofacitinib Citrate, submitted by Saptalis Pharmaceuticals.
Company
Pharmaceutical intelligence for Saptalis Pharmaceuticals with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.